arrow
P

Pietro Mattioli

department of epileptology and cerebral rhythmology
H指数:15
被引数:714

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical markers of disease progression in the prodromal to overt alpha-synucleinopathy continuum

从前驱期到显性阿尔法-突触核蛋白病连续体的疾病进展临床标志物

Brain
IF11.7
2026-05-290
OA
Genetic associations between post-traumatic stress disorder and REM-sleep behavior disorder

创伤后应激障碍与快速眼动睡眠行为障碍之间的遗传关联

2026-05-210
OAAI
[18F]Fluorodeoxyglucose positron emission tomography ([18F]FDG PET) Characterizes Neurodegeneration Levels Across the α-Synucleinopathy Continuum

[18F]氟代脱氧葡萄糖正电子发射断层扫描([18F]FDG PET)表征α-突触核蛋白病连续谱中的神经退行性变水平

2026-04-050
OAAI
Presynaptic dopaminergic imaging as a neurodegeneration staging biomarker in the alpha-synucleinopathy continuum

突触前多巴胺能成像作为α-突触核蛋白病连续谱系中神经退行性变的分期生物标志物

2026-04-010
OAAI
Correction to: Head to head comparison between arterial spin labelling MRI and [18F]FDG-PET in presurgical evaluation of epilepsy in children: the role of voxel-based asymmetry index analysis

更正:动脉自旋标记MRI与[18F]FDG-PET在儿童癫痫术前评估中的头对头比较:基于体素的对称性指数分析的作用

2026-03-260
OAAI
Head to head comparison between arterial spin labelling MRI and [18F]FDG-PET in presurgical evaluation of epilepsy in children: the role of voxel-based asymmetry index analysis

动脉自旋标记MRI与[18F]FDG-PET在儿童癫痫术前评估中的头对头比较:体素级不对称指数分析的作用

2026-02-270
OAAI
MRI susceptibility map weighted imaging (SMWI) as a neurodegeneration biomarker in the prodromal to overt alpha-synucleinopathy continuum

MRI磁化率图加权成像(SMWI)作为从前驱期到显性期阿尔法-突触核蛋白病连续谱中的神经退行性病变生物标志物

2025-12-030
OA
Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson’s disease

基于智能手机的帕金森病前驱期和显性期多巴胺能缺陷的预测

2025-12-010
OAAI
Cerebrospinal fluid NPTX2 and [18F]FDG PET track serotonergic vulnerability to neurodegeneration in prodromal Alzheimer’s disease

脑脊液NPTX2和[18F]FDG PET追踪阿尔茨海默病前驱期中神经退行性变对5-羟色胺能系统的易损性

2025-11-230
OAAI
Lacosamide is Associated with a Higher Treatment Persistence at 12 Months than Brivaracetam and Perampanel Despite Similar Efficacy

拉考沙胺在治疗12个月时的持续性高于布瓦雷萨坦和珀马panel,尽管其疗效相似。

2025-11-200
OAAI
Sex differences in clinical and prognostic trajectories in patients with idiopathic REM sleep behavior disorder: Insights from the FARPRESTO cohort

特发性REM睡眠行为障碍患者临床和预后轨迹的性别差异:来自FARPRESTO队列的见解

2025-11-040
OA
Correction: Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies

更正:磁化率分量揭示了α-突触核蛋白病中神经退行性的不同方面

2025-10-170
OA
Longitudinal changes in [18F]FDG PET brain metabolism as a prognostic marker in autoimmune encephalitis

[18F]FDG PET脑代谢的纵向变化作为自身免疫性脑炎的预后标志物

2025-08-250
OAAI
Trends in epilepsy surgery in Italy before and after the COVID-19 pandemic: A nationwide study

意大利癫痫手术在COVID-19疫情前后的趋势:一项全国性研究

2025-07-280
OAAI
[18F]FDG PET metabolic correlates of cerebrospinal fluid TAR DNA-binding protein 43 in prodromal Alzheimer's disease

[18F]FDG PET代谢与脑脊液TAR DNA-binding protein 43在阿尔茨海默病前驱期的相关性

2025-07-010
OA
Clinical and metabolic profiles in behavioural frontotemporal dementia: Impact of age at onset
CORTEX
IF3.3
2025-04-010
OAAI